ALKEM LABS LTD
GenericsALKEM LABS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.
ALKEM LABS LTD's Key Drugs
ALKEM LABS LTD's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE, AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Gastrointestinal Disorder
Type 2 Diabetes Mellitus
Hypertension
Heart Failure
Hypertension
ALKEM LABS LTD's Recent FDA Approvals
ALKEM LABS LTD secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
ALKEM LABS LTD's Therapeutic Areas
ALKEM LABS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALKEM LABS LTD's Top Competitors
ALKEM LABS LTD's closest competitors by therapeutic-area and drug-target overlap include LEDERLE, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALKEM LABS LTD Pipeline Snapshot
Active clinical trials for ALKEM LABS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (10)
Discontinued (1)
Company Info
- First Approval
- 1985-05-31
- Latest
- 2026-06-18
- Applications
- 161